Evidence map›Paper›PMID 40155960›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025

Differentiating high-grade patterns and predominant subtypes for IASLC grading in invasive pulmonary adenocarcinoma using radiomics and clinical-semantic features.

Sunyi Zheng, Jiaxin Liu, Jiping Xie, Wenjia Zhang, Keyi Bian, Jing Liang, Jingxiong Li, Jing Wang, Zhaoxiang Ye, Dongsheng Yue and 1 more

Abstract read
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sunyi Zheng *Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Jiaxin Liu *Tianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Jiping Xie *Key Laboratory of Cancer Prevention and Therapy, Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Lung Cancer Center, Tianjin, China.
Wenjia ZhangDepartment of Radiology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Keyi BianTianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Jing LiangTianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Jingxiong LiCollege of Computer Science and Technology, Zhejiang University, Hangzhou, China.
Jing WangSchool of Public Health, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Zhaoxiang YeTianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. zye@tmu.edu.cn.
Dongsheng YueKey Laboratory of Cancer Prevention and Therapy, Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Lung Cancer Center, Tianjin, China. yuedongsheng@tmu.edu.cn.
Xiaonan CuiTianjin's Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. cuixiaonan@tjmuch.com.

Funding

National Natural Science Foundation of China 82171932
6 · The paper itself

Abstract

objectivesThe International Association for the Study of Lung Cancer (IASLC) grading system for invasive non-mucinous adenocarcinoma (ADC) incorporates high-grade patterns (HGP) and predominant subtypes (PS). Following the system, this study aimed to explore the feasibility of predicting HGP and PS for IASLC grading. MATERIALS AND

methodsA total of 529 ADCs from patients who underwent radical surgical resection were randomly divided into training and validation datasets in a 7:3 ratio. A two-step model consisting of two submodels was developed for IASLC grading. One submodel assessed whether the HGP exceeded 20% for ADCs, whereas the other distinguished between lepidic and acinar/papillary PS. The predictions from both submodels determined the final IASLC grades. Two variants of this model using either radiomic or clinical-semantic features were created. Additionally, one-step models that directly assessed IASLC grades using clinical-semantic or radiomic features were developed for comparison. The area under the curve (AUC) was used for model evaluation.

resultsThe two-step radiomic model achieved the highest AUC values of 0.95, 0.85, 0.96 for grades 1, 2, 3 among models. The two-step models outperformed the one-step models in predicting grades 2 and 3, with AUCs of 0.89 and 0.96 vs. 0.53 and 0.81 for radiomics, and 0.68 and 0.77 vs. 0.44 and 0.63 for clinical-semantics (p < 0.001). Radiomics models showed better AUCs than clinical-semantic models for grade 3 regardless of model steps.

conclusionsPredicting HGP and PS using radiomics can achieve accurate IASLC grading in ADCs. Such a two-step radiomics model may provide precise preoperative diagnosis, thereby supporting treatment planning.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAgedFemaleHumansMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessRadiomicsRetrospective StudiesTomography, X-Ray ComputedAdenocarcinoma of lungComputed tomographyIASLC gradingPathologyRadiomics

Identifiers

PMID40155960
PMCPMC11951669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.